Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Corixa Bexxar gets review

Executive Summary

GlaxoSmithKline/Corixa's BLA (125011/0) for Bexxar in the treatment of non-Hodgkin's lymphoma will be reviewed by FDA's Oncologic Drugs Advisory Committee on Dec. 17. The companies requested a meeting after receiving a March "complete review" letter from FDA (1"The Pink Sheet" May 20, In Brief). The meeting will begin at 12:30 p.m. at the Holiday Inn in Bethesda, Md. [Editor's note: To view a 2webcast/video of this and other advisory committee meetings, go to FDAAdvisoryCommittee.com]...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS040764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel